AVALO THERAPEUTICS, INC. Deferred Tax Liabilities, Goodwill
AVALO THERAPEUTICS, INC. (AVTX) had Deferred Tax Liabilities, Goodwill of $1.25 million as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill · last filed 2026-03-23
- 2025-12-31: Deferred Tax Liabilities, Goodwill $1.25M.
- 2024-12-31: Deferred Tax Liabilities, Goodwill $1.02M.
- 2023-12-31: Deferred Tax Liabilities, Goodwill $774.00K.
- 2022-12-31: Deferred Tax Liabilities, Goodwill $702.00K.
| Period end | Deferred Tax Liabilities, Goodwill |
|---|---|
| 2025-12-31 | $1.25M 10-K · filed 2026-03-23 |
| 2024-12-31 | $1.02M 10-K · filed 2026-03-23 |
| 2023-12-31 | $774.00K 10-K · filed 2025-03-20 |
| 2022-12-31 | $702.00K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |